GE Ventures and Mayo Clinic have jointly set up a new company to scale and digitise cell and gene therapies.
Known as Vitruvian Networks, the new company will focus on combating cancer and other diseases through advanced software systems and manufacturing services that will expedite patient access to personalised therapies.
Go deeper with GlobalData
Using Mayo Clinic’s data related to biomarkers, cell therapy processes and clinical outcomes, Vitruvian Networks will carry out the development of personalised therapies.
A team of hybrid of life science and software development experts at Vitruvian Networks will initially focus on the production of autologous cell therapies that target blood cancers.
Autologous therapies in the area of regenerative and personalised medicine have shown promising results in treating life-threatening diseases.
GE Ventures CEO Sue Siegel said: “Merging GE’s operational excellence with emerging cell and gene therapies will enable faster, more effective and safer treatments for patients.
“Mayo Clinic is a key leader within patient treatment delivery in cancer care and regenerative medicine, so we are honoured to have incubated this solution in joint partnership.”
The new company will also develop the supporting standards, infrastructure and ecosystem that will protect patients and expedite discovery, delivery and regulation in the field.
It will use tools from GE Healthcare’s cell therapy business in addition to those of other leading partners.
Vitruvian Networks will also have access to the GE Store to repurpose analytical capabilities and manufacturing process excellence from business units, such as GE Healthcare, GE Aviation and GE Power.
